Dystonia update

Clinical Neuropharmacology

Volumn 23, Issue 5, 2000, Pages 239-251

  Bressman, S B ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

Anticholinergics; Botulinum toxin; Dystonia; Dystonia musculorum deformans; Levodopa; Levodopa responsive dystonia; Movement disorders; Oppenheim's disease; Spasmotic torticollis

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN; BOTULINUM TOXIN A; CARBAMAZEPINE; CARBIDOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; LEVODOPA; TETRABENAZINE;

AUTOSOMAL DOMINANT DISORDER; DYSTONIA; HUMAN; MYOCLONUS; PALLIDOTOMY; PRIORITY JOURNAL; REVIEW; TORSION DYSTONIA;

BACLOFEN; BASAL GANGLIA; CHOLINERGIC ANTAGONISTS; DYSTONIA; DYSTONIA MUSCULORUM DEFORMANS; HUMANS; LEVODOPA; MUSCLE RELAXANTS, CENTRAL;

EID: 0034545339     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200009000-00002     Document Type: Review

References (146)

1. Classification and investigation of dystonia
2. Classification of dystonia
3. Tremor and idiopathic dystonia
4. Neurophysiologic investigation in patients with head tremor
5. Improvement of laryngeal dystonia with background noise
6. Exteroceptive and interoceptive stimuli in dystonia
7. Clinical variants of idiopathic torsion dystonia
8. Relationship between sleep, neck muscle activity, and pain in cervical dystonia
9. Idiopathic cervical dystonia: Clinical characteristics
10. Pain in spasmodic torticollis
11. Natural history of idiopathic torsion dystonia
12. Concept and classification of dystonia
13. Dystonic disorders
14. Spread of symptoms in idiopathic torsion dystonia
15. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale
16. Fine localization of the dystonia gene (DYT1) on human chromosome 9q34:YAC map and linkage disequilibrium
17. Epidemiology of focal and generalized dystonia in Rochester, Minnesota
18. Dystonia musculorum deformans; clinical, genetic and pathoanatomic studies
19. Inheritance of idiopathic torsion dystonia among Jews
20. Genetic analysis of idiopathic torsion dystonia in Ashkenazi Jews and their recent descent from a small founder population
21. Idiopathic torsion dystonia among Ashkenazi Jews: Evidence for autosomal dominant inheritance
22. A genetic study of idiopathic torsion dystonia in the United Kingdom
23. Complex segregation analysis of dystonia pedigrees suggests autosomal dominant inheritance
24. Human gene for torsion dystonia located on chromosome 9q32-34
25. The DYT1 gene on 9q34 is responsible for most cases of early-onset idiopoathic torsion dystonia in non-Jews
26. Linkage analysis in British families with idiopathic torsion dystonia
27. Strong allelic association between the torsion dystonia gene (DYT1) and loci on chromosome 9q34 in Ashkenazi Jews
28. Dystonia in Ashkenazi Jews: Clinical characterization of a founder mutation
29. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein
30. A case of primary torsion dystonia in Japan with the 3-bp (GAG) deletion in the DYT1 gene with a unique clinical presentation
31. The role of primary torsion dystonia in Europe
32. A common 3-bp deletion in the DYT1 gene in Russian families with early-onset torsion dystonia
33. DYT1 Mutation in French families with idiopathic torsion dystonia
34. De novo mutations (GAG deletion) in the DYT1 gene in two non-Jewish patients with early-onset dystonia
35. Expression of early-onset torsion dystoni gene (DYT1) in human brain
36. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult brain
37. The DYT1 phenotype and guidelines for diagnostic testing
38. Genetic contribution to idiopathic adult-onset blepharospasm and cranial-cervical dystonia
39. Inheritance of late-onset idiopathic torsion dystonia
40. A genetic study of idiopathic focal dystonias
41. A genetic study of idiopathic focal dystonias
42. Frequency of familial inheritance among 488 index patients with idiopathic focal dystonia and clinical variability in a large family
43. Primary torsion dystonia: The search for genes is not over
44. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families
45. Idiopathic torsion dystonia: Assignment of a gene to chromosome 18p in a German family with adult onset, autosomal inheritance and purely focal distribution
46. Sporadic focal dystonia in northwest Germany: Molecular basis on chromosome 18p
47. Evidence for DYT7 being a common cause of cervical dystonia in central Europe
48. Search for a founder mutation in idiopathic focal dystonia from northern Germany
49. Pathology in brainstem regions of individuals with primary dystonia
50. Increased tissue copper and manganese content in the lentiform nucleus in primary adult-onset dystonia
51. Lenticular nucleus lesion in idiopathic torsion dystonia detected by transcranial sonography
52. Comparison of transcranial sonography, magnetic resonance imaging, and single photon emission computed tomography findings in idiopathic spasmodic torticollis
53. Prolonged MRI T-2 times of the lentiform nucleus in idiopathic spasmodic torticollis
54. Electron transfer complex-1 defect in idiopathic dystonia
55. Complex 1 function in familial and sporadic dystonia
56. Respiratory chain and mitochondrial deoxyribonucleic acid in blood cells from patients with focal and generalized dystonia
57. The pathophysiology of dystonia
58. The anatomic and physiologic basis of torsion dystonia
59. Reciprocal inhibition in writer's and other occupational cramps and hemiparesis due to stroke
60. H-reflex recovery curve and reciprocal inhibition of H-reflex in different kinds of dystonia
61. Modulation of electromyographic activity of wrist flexor and extensor muscles in pateints with writer's cramp
62. Blink reflex excitability recovery curves in patients with spasmodic dysphonia
63. Movement-related cortical potentials in writer's cramp
64. Botulinum toxin does not reverse the cortical dysfunction associated with writer's cramp: A PET study
65. Abnormal sensorimotor integration in writer's cramp: Study of contingent negative variation
66. Tonic vibration reflex and muscle afferent block in writer's cramp
67. Impaired inhibition in writer's cramp during voluntary muscle activation
68. Impairment of cortical inhibition in writer's cramp as revealed by changes in electro-myographic silent period after transcranial magnetic stimulation
69. A primate genesis model of focal dystonia and repetitive strain injury: Learning-induced dedifferentiation of the representation of the hand in the primary somatosensory cortex in adult mokeys
70. Thalamic single neuron activity in patients with dystonia: Dystonia-related activity and somatic sensory reorganization
71. Abnormal sensory homunculus in dystonia of the hand
72. Temporal discrimination of somaesthetic stimuli is impaired in dystonic patients
73. Neuronal avtivity in the basal ganglia in patients with generalized dystonia and hemiballism
74. Decreased [F-18]spiperone binding in putamen in idiopathic focal dystonia
75. Cerebral glucose metabolism in patients with spasmodic torticollis
76. The metabolic topography of idiopathic torsion dystonia
77. Functional brain networks in DYT1 dystonia
78. Lesions of the putamen and dystonia: CT and magnetic resonance imaging
79. The behavioral and motor consequences of focal lesions of the basal ganglia in man
80. The anatomic basis of symptomatic hemidystonia
81. Hemidystonia: A report of 22 patients and a review of the literature
82. Hand dystonia secondary to cervical demyelinating lesion
83. Cervical dystonia associated with tumors of the posterior fossa
84. Cervical dystonia due to a spinal cord ependymoma: Involvement of the cervical cord segments in the pathogenesis of dystonia
85. Striatopallidal and thalamic dystonia: A magnetic resonance imaging anatomoclinical study
86. Symptomatic dystonias associated with brain structural lesions: Report of 16 cases
87. Unilateral blepharospasm stemming form a thalamomesencephalic lesion
88. Blepharospasm in association with a lower pontine lesion
89. Focal dystonia after chemotherapy: A case series
90. Delayed segmental axial dystonia of the trunk on standing after lumbar disk operation
91. Cervical dystonia associated with tumors of the posterior fossa
92. Lingual dystonia following electrical injury
93. Dystonia in progressive supranuclear palsy
94. Cervical dystonia as the initial presentation of Huntington's disease
95. Rapid-onset dystonia-parkinsonism in a second family
96. Rapid-onset dystonia-parkinsonism in a 14 year old girl
97. Rapid-onset dystonia-parkinsonism: Linkage to chromosome 19q13
98. Variable phenotype of rapid-onset dystonia-parkinsonism
99. Dopa-responsive dystonia: Long-term treatment response and prognosis
100. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia
101. Typical parkinsonism in dopa-responsive dystonia
102. GCH1 mutation in a apetint with adult-onset oromandibular dystonia
103. Remission in dihydroxyphenylalanine-responsive dystonia
104. Dopa-responsive dystonia simulating cerebral palsy
105. Dopa-responsive childhood dystonia: A formes frustes with writer's cramp, triggered by exercise
106. Dystonia with motor delay in compound heterozygotes for GTP cylcohydrolase I gene mutations
107. GTP cyclohydrolase I mutations in patients with dystonia responsive to anticholinergic drugs
108. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase gene
109. GTP cyclohydrolase I mutations in hereditary progressive and dopa responsive dystonia
110. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in doparesponsive dystonia
111. Recessively inherited L-Dopa responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene
112. Recessively inherited L-Dopa -responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene
113. 6-pyrovoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: A clinical molecular study
114. Dopa-responsive dystonia in British patients: New mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity
115. [123]beta-CIT single photon emission tomography in dopa-responsive dystonia
116. 11C]-raclopride and positron emission tomography
117. Oral phenylalanine loading in dopa-responsive dystonia: A possible diagnostic test
118. Alcohol responsive myoclonic dystonia in a large family: Dominant inheritance and phenotypic variation
119. Essential myoclonus and myoclonic dystonia
120. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia
121. Localization of e gene for myoclonus dystonia to chromosome 7q21-31
122. Torsion dystonia: A double blind, prospective trial of high dosage trihexyphenidyl
123. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs
124. Baclofen in the treatment of idiopathic dystonia in children
125. The treatment of severe dystonia in children and adults
126. Tetrabenazine treatment in dystonia, chorea, tics, and other dyskinesias
127. Efficacy of risperidone in idiopathic segmental dystonia
128. Use of intrathecal baclofen in patients with dystonia
129. Globus pallidus internus pallidotomy for generalized dystonia
130. Functional recovery after bilateral pallidotomy for the treatment of early-onset primary generalized dystonia
131. Globus pallidus deep brain stimulation for generalized dystonia: Clinical and PET investigation
132. Treatment of putative immune-mediated idiopathic cervical dystonia with intravenous methylprednisolone
133. Mexilitine in the treatment of spasmodic torticollis
134. Botulinum A toxin injections for cranial-cervical dystonia: A double blind placebo controlled study
135. Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective randomized double-blind controlled trial
136. Long-term treatment of cervical dystonia with botulinum toxin A: Eficacy, safety, and antibody formation
137. An open-label study of botulinum toxin A for treatment of tardive dystonia
138. Botulinum toxin therapy: Neutralizing and non-neutralizing antibodies - Therapeutic consequences
139. Mouse bioassay versus Western blot assay for botulinum toxin antibodies: Correlation with clinical resonse
140. Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies
141. Botulinum toxin type B: A double-blind placebo-controlled, safety and efficacy study of cervical dystonia
142. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia patients
143. Botulinum neurotoxin serotype C: A novel effective botulinum toxin therapy in human
144. Selective peripheral denervation in 111 cases of spasmodic torticollis: Rationale and results
145. Symptomatic and functional outcome of surgical treatment of cervical dystonia
146. Bilateral stimulation of globus pallidus internus for treatment of cervical dystonia